It was a process five years in the making. The QEII Health Sciences Centre’s cyclotron was granted a Drug Establishment Licence (DEL) from Health Canada in June 2015, a major step forward — not just for Nova Scotia, but for all Atlantic Canadians.
The cyclotron creates medical isotopes, primarily fluorodeoxyglucose (FDG), in which a minuscule amount of radioactive material is used to power the QEII’s positron emission tomography-computed (PET CT) scanner, used to diagnose diseases such as cancer. As the flagship project of a major fundraising campaign, the QEII’s cyclotron and PET CT received funding ... Before the QEII gained its cyclotron, it had to receive all of its FDG from Montreal. Unfortunately, the isotopes deteriorate with time, so getting the product on a reliable basis became problematic. Read more.